Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 5 for:    restorbio
Previous Study | Return to List | Next Study

A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04584710
Recruitment Status : Active, not recruiting
First Posted : October 14, 2020
Last Update Posted : February 9, 2021
Sponsor:
Collaborator:
National Institute on Aging (NIA)
Information provided by (Responsible Party):
Restorbio Inc.

Brief Summary:
The proposed trial will obtain preliminary data on the feasibility of studying RTB101 as compared to placebo for COVID-19 post-exposure prophylaxis in adults age ≥ 65 years to inform the design of a subsequent pivotal trial.

Condition or disease Intervention/treatment Phase
Covid19 Drug: RTB101 Drug: Placebo Phase 2

Detailed Description:
The RTB101-211 study is a Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Asymptomatic Adults Age ≥65 Years who: have SARS-CoV-2 detected on a surveillance nasal or nasopharyngeal swab OR live in the same house or apartment as someone who has laboratory-confirmed symptomatic COVID-19. The study is designed to obtain study feasibility data for RTB101 in an unbiased fashion and will inform the design of a subsequent pivotal trial.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Adults Age ≥65 Years
Actual Study Start Date : October 13, 2020
Estimated Primary Completion Date : February 2021
Estimated Study Completion Date : February 2021

Arm Intervention/treatment
Experimental: 10 mg daily RTB101

RTB101

TORC1 inhibitor

Drug: RTB101
Oral RTB101 10 mg hard gelatin capsule once daily for 2 weeks
Other Names:
  • Dactolisib
  • BEZ235

Placebo Comparator: Placebo
Placebo
Drug: Placebo
Oral matching placebo once daily for 2 weeks
Other Name: Placebo capsule




Primary Outcome Measures :
  1. To determine the length of time from date of receipt of a positive SARS-CoV2 test result to date of first dose of study drug in asymptomatic adults age ≥ 65 years [ Time Frame: Beginning of randomization through Week 2 ]

    The number of days from the date of receipt of a positive SARS-CoV-2 swab test result to the date of first dose of study drug in asymptomatic subjects who:

    • have SARS-CoV-2 detected on a surveillance nasal or nasopharyngeal swab OR
    • live in the same house or apartment as someone who has laboratory-confirmed symptomatic COVID-19


Secondary Outcome Measures :
  1. To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population [ Time Frame: Beginning of randomization through Week 2 ]
    Study drug compliance determined from the number of capsules of study drug taken by the subject based on data reported in an eDiary

  2. To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population [ Time Frame: Beginning of randomization through Week 2 ]
    Study drug compliance determined from the number of capsules of study drug taken by the subject based on data from twice weekly phone calls

  3. To determine the feasibility of using an eDiary to assess study drug compliance in the study drug population [ Time Frame: Beginning of randomization through Week 2 ]
    Study drug compliance determined from the number of capsules of study drug taken by the subject based on a pill count done by phone when subjects complete study drug treatment

  4. To determine the feasibility of using an eDiary to assess COVID-19 symptoms in the study population [ Time Frame: From time of first dose through Week 3 ]
    Incidence and severity of COVID-19 symptoms based on data reported in an eDiary

  5. To determine the feasibility of using an eDiary to assess COVID-19 symptoms in the study population [ Time Frame: From time of first dose through Week 3 ]
    Incidence and severity of COVID-19 symptoms based on data from twice weekly phone calls

  6. To assess the incidence of treatment-emergent of AEs and SAEs in subjects assigned to RTB101 as compared to placebo [ Time Frame: From time of first dose through Week 3 ]
    Safety and tolerability will be assessed by report of AE/SAEs from first dose of study drug through Week 3

  7. To determine the percentage of subjects treated with RTB101 as compared to placebo who develop symptomatic laboratory-confirmed COVID-19 from first dose through Day 14 [ Time Frame: From time of first dose through Week 2 ]
    The percentage of subjects who have SARS-CoV-2 detected on nasal or nasopharyngeal swab and who develop 2 or more concurrent symptoms of COVID-19 from first dose of study drug through Day 14

  8. To determine the percentage of subjects treated with RTB101 as compared to placebo who die from any cause from first dose of study drug through Day 14 and 21 [ Time Frame: From time of first dose through Week 3 ]
    The percentage of subjects who die from any cause from first dose of study drug through Day 14 and 21

  9. To determine the percentage of subjects treated with RTB101 as compared to placebo who develop laboratory-confirmed COVID-19 from first dose through Day 14 and are subsequently hospitalized for any reason through Day 21 [ Time Frame: From time of first dose through Week 3 ]
    The percentage of subjects who develop laboratory-confirmed COVID-19 from first dose of study drug through Day 14 and are subsequently hospitalized for any reason through Day 21

  10. To determine the percent of subjects treated with RTB101 or placebo who have laboratory-confirmed SARS-CoV-2 infection regardless of symptoms from first dose of study drug through Days 7, 14, 21. [ Time Frame: From time of first dose through Week 3 ]
    The percentage of subjects who have SARS-CoV-2 detected on nasal or nasopharyngeal swab regardless of symptoms from first dose of study drug through Day 7, 14, and 21 among subjects who are not SARS-CoV-2 positive at screening or baseline



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years and older   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
  1. Informed consent must be obtained from the subject before any assessment is performed.
  2. Adults (male and female) aged 65 years and over who are asymptomatic but:

    1. have SARS-CoV-2 detected during surveillance nasal or nasopharyngeal swab testing OR
    2. live in the same house or apartment as someone who has laboratory-confirmed symptomatic COVID-19 .
  3. Sexually active male subjects with a partner of child-bearing potential must be willing to wear a condom while on study drug and for 1 week after stopping study drug and should not father a child in this period. A condom is required to be used also by vasectomized men with a partner of child-bearing potential to prevent delivery of the drug via seminal fluid.
  4. Subject must be able to understand and comply with the requirements of the study including having internet access and an email account, willingness to answer an eDiary questionnaire on a personal electronic device each night, and willingness to answer the telephone questionnaires twice weekly

Exclusion Criteria:

  1. Any subject who self-reports:

    1. As a current smoker, or stopped smoking within the past 6 months.
    2. As a previous smoker with a ≥10 pack year smoking history.
    3. Has a household member who currently smokes in the house.
  2. Subjects with a medical history of chronic obstructive pulmonary disease (COPD), emphysema or chronic bronchitis requiring active treatment with a prescription medication
  3. The subject has already had symptoms consistent with COVID-19 at screening.
  4. Subjects who require chronic supplemental oxygen therapy at screening.
  5. Subjects with current evidence of an unstable medical disorder including an unstable respiratory disorder, gastrointestinal disorder (including Child-Pugh class B and C hepatic impairment), renal disorder or hematologic disorder (including active leukemia) for which they have had an exacerbation of symptoms within the past month, or are undergoing a change in treatment.
  6. The following cardiac conditions:

    1. Unstable angina pectoris
    2. History of myocardial infarction (MI), coronary bypass surgery, or any percutaneous coronary intervention (PCI) within 6 months prior to Screening
    3. Congestive heart failure requiring active treatment with a prescription medication
    4. Unstable or life-threatening cardiac arrhythmia

    a. Chronic stable atrial fibrillation is allowed

  7. Subjects with a history of systemic autoimmune diseases (e.g., lupus, inflammatory bowel disease, rheumatoid arthritis, etc.).

    a. Psoriasis confined to the skin and eczema are allowed

  8. Subjects receiving immunosuppressive therapy including chronic use of supraphysiologic steroids such as prednisone >10 mg daily (however, inhaled corticosteroids and acute use of higher doses of prednisone to treat conditions such as exacerbation of asthma or other acute conditions are allowed).
  9. Subjects with an immunodeficiency disease, including a history of a positive human immunodeficiency virus (HIV) test result.
  10. Subjects with a history of gastric bypass surgery.
  11. Subjects who require treatment with strong CYP3A4 or CYP1A2 inhibitors or inducers, or subjects who require treatment with digoxin.
  12. Use of any other investigational medication or participation in any other investigational study within 5 half-lives of the investigational medication, or within 30 days, whichever is longer; or longer if required by local regulations.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04584710


Locations
Layout table for location information
United States, Connecticut
University of Connecticut, UConn Center on Aging
Farmington, Connecticut, United States, 06030
United States, Massachusetts
Hebrew Senior Life, Marcus Institute for Aging Research
Roslindale, Massachusetts, United States, 02131
Sponsors and Collaborators
Restorbio Inc.
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Study Director: Medical Monitor Restorbio Inc.
Layout table for additonal information
Responsible Party: Restorbio Inc.
ClinicalTrials.gov Identifier: NCT04584710    
Other Study ID Numbers: RTB101-211
3R01AG064802-02S1 ( U.S. NIH Grant/Contract )
First Posted: October 14, 2020    Key Record Dates
Last Update Posted: February 9, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Restorbio Inc.:
Mechanistic Target of Rapamycin (mTOR)
Virus
Additional relevant MeSH terms:
Layout table for MeSH terms
Dactolisib
Antineoplastic Agents